Stay updated with breaking news from Nasdaq Fdmt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) insider Scott Bizily sold 1,909 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $30.00, for a total value of $57,270.00. Following the sale, the insider now owns 1,737 shares in the company, valued at […]
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) – Equities research analysts at Leerink Partnrs raised their Q4 2023 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a research note issued to investors on Wednesday, February 7th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($0.39) per […]
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) traded up 9.4% during mid-day trading on Friday . The company traded as high as $29.53 and last traded at $29.43. 779,157 shares traded hands during trading, a decline of 50% from the average session volume of 1,558,401 shares. The stock had previously closed […]
EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company...